^
    10d
    This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=55, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial • First-in-human
    11d
    TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC (clinicaltrials.gov)
    P1, N=24, Recruiting, TCRCure Biopharma Ltd.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    11d
    To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004 (clinicaltrials.gov)
    P=N/A, N=11, Not yet recruiting, Starna Therapeutics
    New trial
    14d
    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Beijing GoBroad Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    25d
    Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity. (PubMed, Mol Cancer Ther)
    The highest non-severely toxic dose was 5×108 CAR-T cells/kg. In the clinical case report, we present a case with unresectable advanced gastric cancer achieved pathological complete response 10 months after IMC002 infusion and no signs of recurrence were indicated in subsequent clinical and radiological follow-ups. IMC002 shows effectiveness and safety in CLDN18.2-positive gastric and pancreatic cancer and its favorable profiles support further clinical development.
    Preclinical • Journal
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    IMC002
    2ms
    A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=28, Recruiting, Grit Biotechnology
    New P1 trial
    |
    denfivontinib (SKI-G-801)
    2ms
    A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    2ms
    Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia. (PubMed, Leukemia)
    We also demonstrate that removal of shared CD7 antigens enabled compatibility of BE-CAR33 and BE-CARCLL-1 with BE-CAR7 T cells, including in a patient-derived xenograft (PDX) model of AML. Therapeutic strategies envisage 'pick and mix' applications of base edited "universal" CAR T cells in combination determined by patient-specific antigen profiles. Such approaches also offer the possibility of deep, cell-based, de-bulking and conditioning ahead of allo-SCT and subsequent donor-derived reconstitution.
    Journal • IO biomarker
    |
    CD33 (CD33 Molecule)
    |
    BE CAR7 T
    2ms
    A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=20, Recruiting, First Affiliated Hospital of Zhejiang University
    New P1 trial
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    3ms
    A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, Calibr, a division of Scripps Research | Active, not recruiting --> Recruiting
    Enrollment open
    3ms
    BC19IGG4: Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease (clinicaltrials.gov)
    P2, N=9, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    cyclophosphamide • fludarabine IV
    3ms
    BC19IGG4: Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease (clinicaltrials.gov)
    P2, N=9, Not yet recruiting, Chinese PLA General Hospital
    New P2 trial • IO biomarker
    |
    cyclophosphamide • fludarabine IV